title: Malignant potential in pancreatic neoplasm; new insights provided by circulating miR-223 in plasma.
abstract: BACKGROUND
  Recent studies have identified that microRNAs are stably detectable in plasma/serum because of their binding to specific proteins or being packaged in secretory vesicles.
  
  
  METHODS
  We tested miR-223 as a candidate of novel plasma biomarker in pancreatic cancer (PCa) and intraductal papillary mucinous neoplasm (IPMN).
  
  
  RESULTS
  i) miR-223 expression was significantly higher in PCa tissues (p = 0.0069) than in normal tissues. ii) Plasma miR-223 levels were significantly higher in 71 PCa patients than 67 healthy volunteers (p < 0.0001). iii) Plasma miR-223 levels were significantly reduced in postoperative samples (p = 0.0297). iv) Plasma miR-223 levels tended to discriminate the malignant potential between benign IPMN and malignant IPMN (p = 0.0963), and the progressive extent of invasiveness between malignant IPMN and pancreatic invasive ductal carcinoma (PIDC) (p = 0.0004). Multivariate logistic regression analysis revealed that a low level of plasma miR-223 was an independent risk factor for PIDC (p = 0.0012, odds ratio 7.90 [95% CI: 2.06 - 41.2]). v) There was no significant correlation between plasma miR-223 levels and the number of any blood cell types in the peripheral blood.
  
  
  CONCLUSIONS
  Plasma miR-223 might be a clinically useful biomarker for screening PCa, and predicting malignant potential of IPMN and the invasiveness of PCa.
authors.affiliation: Kyoto Prefectural University of Medicine, Division of Digestive Surgery, Department of Surgery , 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto , Japan +81 75 251 5527 ; +81 75 251 5522 ; skomatsu@koto.kpu-m.ac.jp.
authors.forename: Shuhei
authors.initials: S
authors.lastname: Komatsu
authors.forename: Daisuke
authors.initials: D
authors.lastname: Ichikawa
authors.forename: Mahito
authors.initials: M
authors.lastname: Miyamae
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Kawaguchi
authors.forename: Ryo
authors.initials: R
authors.lastname: Morimura
authors.forename: Shoji
authors.initials: S
authors.lastname: Hirajima
authors.forename: Wataru
authors.initials: W
authors.lastname: Okajima
authors.forename: Takuma
authors.initials: T
authors.lastname: Ohashi
authors.forename: Taisuke
authors.initials: T
authors.lastname: Imamura
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Konishi
authors.forename: Atsushi
authors.initials: A
authors.lastname: Shiozaki
authors.forename: Hisashi
authors.initials: H
authors.lastname: Ikoma
authors.forename: Kazuma
authors.initials: K
authors.lastname: Okamoto
authors.forename: Hiroki
authors.initials: H
authors.lastname: Taniguchi
authors.forename: Eigo
authors.initials: E
authors.lastname: Otsuji
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000097:blood / Q000175:diagnosis; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood; D021441:Carcinoma, Pancreatic Ductal / Q000097:blood* / Q000175:diagnosis*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000097:blood*; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology; D010179:Pancreas / Q000378:metabolism / Q000473:pathology; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000175:diagnosis*
chemical_list: D014408:Biomarkers, Tumor; D035683:MicroRNAs; C525067:MIR223, human
keywords: biomarker; intraductal papillary mucinous neoplasm; liquid biopsy; microRNA; pancreatic cancer; pancreatic invasive ductal carcinoma; plasma; prognosis